Hanmi Science Co Ltd

Hanmi Science maintains a debt-to-equity ratio of 0.28, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is characterized as medium risk, with a current ratio of 0.67, suggesting that its current liabilities exceed its current assets. Despite a negative net cash position after subtracting total debt, the firm reported free cash flow of 32.17 billion KRW, which supports ongoing operations and potential reinvestment.

Profitability metrics show a return on equity (ROE) of 3.93% and a return on assets (ROA) of 2.53%, both below the industry median for pharmaceutical firms. These figures suggest that Hanmi Science is generating returns, but at a slower pace compared to its peers. The company's operating income of 37.3 billion KRW and net income of 31.74 billion KRW reflect a healthy gross margin of 19.23%, but the ROE and ROA figures indicate room for improvement in asset utilization and equity returns.

Geographically, Hanmi Science is concentrated in the South Korean market, with no disclosed international revenue segments. The company's business is primarily driven by its oncology and rare disease drug portfolio, with no material diversification across therapeutic areas or geographic regions. This concentration increases exposure to domestic regulatory and reimbursement risks.

Looking ahead, Hanmi Science is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. The company's capital expenditure of -1.25 billion KRW indicates a reduction in investment in physical assets, which may reflect a shift toward R&D or a more conservative approach to infrastructure spending. The firm's operating cash flow of -535.11 million KRW highlights a short-term liquidity challenge, though the free cash flow remains positive.

Risk factors include the company's medium liquidity risk and the potential for regulatory changes in the South Korean pharmaceutical market. The risk of dilution is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on a limited number of therapeutic areas and geographic markets increases its vulnerability to market-specific disruptions.

Recent filings and disclosures indicate a focus on maintaining financial stability and managing debt levels. The company has not issued new shares in the past year, and there are no material changes in its capital structure or business strategy. The ESG score of 26.18 and a C- rating suggest that the company has room for improvement in environmental, social, and governance practices.

Hanmi Science Co Ltd (008930.KS) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with the broader healthcare industry landscape. Alongside this classification, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently rated as low, suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. Conversely, liquidity risk has been assessed at a medium level. This indicates that while the company maintains operational stability, investors should monitor its cash flow dynamics and short-term asset convertibility more closely than they would for entities with low liquidity risk. These updates occur against a backdrop of limited external coverage, with only one analyst currently tracking the stock and no reported index memberships or top holder data. The establishment of these baseline risk and sector metrics offers a foundational reference point for future financial and ESG analysis [doc:008930.ks-ha-financials] [doc:008930.ks-ha-esg].

Net income surged 99.2% year-over-year to 118.4 billion KRW, demonstrating strong profitability recovery.

Operating income grew 57.0% to 138.7 billion KRW, indicating significant improvement in core operational efficiency.

Free cash flow increased 171.4% to 92.3 billion KRW, providing substantial liquidity for future investments.

The company faces high credit risk, potentially signaling underlying financial instability or counterparty concerns.

Cash conversion ratio of -0.02 places the firm in the bottom quartile of its pharmaceutical cohort.

Debt-to-equity ratio of 0.28 is below the cohort median, suggesting potentially under-leveraged capital structure.

Return on equity of 3.9% remains modest despite recent income growth, indicating limited shareholder value creation.

Medium liquidity risk flags potential challenges in meeting short-term financial obligations efficiently.